Micron Technology, Inc. (MU), and How to Profit From These Double Digit Growers
Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you.
Vertex Pharmaceuticals Inc / Ma (VRTX)
Market is closed
News
- First
- << Previous
- 201 - 210
Johnson & Johnson (JNJ), And Why The FDA's Latest Designation is More Bling Than Bite
Johnson & Johnson (NYSE:JNJ) announced on Monday that it had received a third Breakthrough Therapy Designation for the blood cancer drug ibrutinib that it's developing with Pharmacyclics, Inc.
The Perfect Cure for Hepatitis C? - Gilead Sciences, Inc. (GILD), Johnson & Johnson (JNJ)
Gilead Sciences, Inc. (NASDAQ:GILD)' sofosbuvir with Johnson & Johnson (NYSE:JNJ) and Medivir's simeprevir are a match made in heaven.
Hepatitis C In Play for 2013?: Idenix Pharmaceuticals, Inc. (IDIX)
In the world of biotech stocks a lot of companies are starting to incorporate Hepatitis C treatments into their pipelines.
This Is One Incredible CEO: Vertex Pharmaceuticals Incorporated (VRTX)
The Motley Fool's readers have spoken, and I have heeded your cries.
The FDA Made Biotech Investing Harder (But More Lucrative): Johnson & Johnson (JNJ)
For instance, it's hard to make money on shoo-in Food and Drug Administration approvals. The approval is already reflected in the price.
Celgene Corporation (CELG): My Favorite Big Biotech for 2013
The biggest biopharmaceutical companies blazed trails and lifted portfolios last year.
Has Gilead Sciences, Inc. (GILD) Become the Perfect Stock?
One thing's for sure: You'll never discover truly great investments unless you actively look for them. Let's discuss the ideal qualities of a perfect stock, then decide if Gilead Sciences, Inc.
Gilead Sciences, Inc. (GILD): Piling on the Phase 3 Data
At this point, it looks extremely likely that sofosbuvir will be approved by the FDA. Previous data, released last November, showed the drug worked in patients with genotype 2 or 3 hepatitis C virus.
- First
- << Previous
- 201 - 210
Billionaire Hedge Funds
